Isodiol International Inc. Subsidiary, BSPG Laboratories LTD., Launches API Sales and Marketing Program at CPhI 2018
BSPG Laboratories introduces cannabidiol (CBD) API to over 45,000 pharmaceutical industry professionals from over 150 countries at the world’s largest pharmaceutical event in Spain1
VANCOUVER, British Columbia, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL ) (OTCQB: ISOLF ) (FSE: LB6A.F ) (the “Company” or “Isodiol”), is pleased to offer a reliable source of GMP-compliant cannabidiol (CBD), extracted from industrial hemp to pharmaceutical companies and research groups for human and animal use at CPhI 2018 in Madrid, Spain.
BSPG Laboratories, a U.K.-based subsidiary of Isodiol, is a manufacturer of GMP-compliant pure, natural CBD containing no THC and maintains industry standards while focusing on leading scientific and pharmaceutical methods. The facility was recently registered with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
BSPG Laboratories manufactures non-synthetic CBD as an API for pharmaceutical applications as well as research and clinical studies to benefit the scientific and health care community – on a global level.
Isodiol CEO, Marcos Agramont said, “CPhI is a 28-year established pharmaceutical event bringing together over 45,000 industry professionals2. We are excited to be taking the lead of supplying CBD as an API to the pharmaceutical industry.”
Meet with BSPG Laboratories at CPhI, October 9 – 11, 2018, Hall 5 booth 3H27. For additional information or to contact BSPG Laboratories, please visit BSPGlabs.com.
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARDMarcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
1 https://www.cphi.com/2 https://www.cphi.com/